Nutriband Announces 25% Preferred Stock Dividend as it targets filing for FDA approval
Nutriband (NASDAQ:NTRB) has declared a 25% preferred stock dividend, where shareholders will receive one preferred share for every four common shares held as of July 25th, 2025, with distribution set for August 5th. The preferred shares are convertible to common stock upon FDA approval of AVERSA Fentanyl product.
These preferred shares will be eligible for annual cash dividends from company profits if not converted. CEO Gareth Sheridan emphasized the company's focus on shareholder value creation and highlighted recent progress with Kindeva on commercialization manufacturing as they prepare for FDA approval submission.
Nutriband (NASDAQ:NTRB) ha dichiarato un dividendo azionario preferenziale del 25%, in base al quale gli azionisti riceveranno una azione preferenziale ogni quattro azioni ordinarie possedute al 25 luglio 2025, con distribuzione prevista per il 5 agosto. Le azioni preferenziali sono convertibili in azioni ordinarie al momento dell'approvazione FDA del prodotto AVERSA Fentanyl.
Queste azioni preferenziali avranno diritto a dividendi annuali in contanti derivanti dai profitti aziendali se non convertite. Il CEO Gareth Sheridan ha sottolineato l'attenzione della società alla creazione di valore per gli azionisti e ha evidenziato i recenti progressi con Kindeva nella produzione per la commercializzazione, mentre si preparano alla presentazione per l'approvazione FDA.
Nutriband (NASDAQ:NTRB) ha declarado un dividendo en acciones preferentes del 25%, donde los accionistas recibirán una acción preferente por cada cuatro acciones ordinarias que posean al 25 de julio de 2025, con distribución programada para el 5 de agosto. Las acciones preferentes son convertibles en acciones ordinarias tras la aprobación de la FDA del producto AVERSA Fentanyl.
Estas acciones preferentes serán elegibles para dividendos en efectivo anuales provenientes de las ganancias de la empresa si no se convierten. El CEO Gareth Sheridan destacó el enfoque de la compañía en la creación de valor para los accionistas y resaltó los avances recientes con Kindeva en la fabricación para la comercialización mientras se preparan para la presentación de la aprobación de la FDA.
Nutriband (NASDAQ:NTRB)는 25% 우선주 배당을 선언했으며, 주주들은 2025년 7월 25일 기준으로 보유한 보통주 4주당 1주의 우선주를 받게 되며, 배당은 8월 5일에 지급될 예정입니다. 우선주는 AVERSA 펜타닐 제품의 FDA 승인 시 보통주로 전환할 수 있습니다.
이 우선주는 전환하지 않을 경우 회사 이익에서 연간 현금 배당을 받을 수 있습니다. CEO 가레스 셰리던은 주주 가치 창출에 대한 회사의 집중을 강조하며, FDA 승인 제출 준비를 위해 Kindeva와의 상업용 제조 분야에서 최근 진전을 강조했습니다.
Nutriband (NASDAQ:NTRB) a déclaré un dividende en actions préférentielles de 25%, où les actionnaires recevront une action préférentielle pour quatre actions ordinaires détenues au 25 juillet 2025, avec une distribution prévue le 5 août. Les actions préférentielles sont convertibles en actions ordinaires après approbation de la FDA du produit AVERSA Fentanyl.
Ces actions préférentielles donneront droit à des dividendes annuels en espèces issus des bénéfices de l'entreprise si elles ne sont pas converties. Le PDG Gareth Sheridan a souligné l'engagement de la société à créer de la valeur pour les actionnaires et a mis en avant les récents progrès avec Kindeva dans la fabrication commerciale en préparation de la soumission pour l'approbation FDA.
Nutriband (NASDAQ:NTRB) hat eine 25% Dividende in Vorzugsaktien angekündigt, bei der Aktionäre für je vier gehaltene Stammaktien eine Vorzugsaktie erhalten, basierend auf dem Stand vom 25. Juli 2025, mit Auszahlungstermin am 5. August. Die Vorzugsaktien sind in Stammaktien wandelbar, sobald die FDA die AVERSA Fentanyl-Produkte genehmigt.
Diese Vorzugsaktien berechtigen, falls sie nicht umgewandelt werden, zu jährlichen Bardividenden aus den Unternehmensgewinnen. CEO Gareth Sheridan betonte den Fokus des Unternehmens auf die Schaffung von Aktionärswert und hob die jüngsten Fortschritte mit Kindeva bei der kommerziellen Herstellung hervor, während man sich auf die FDA-Zulassung vorbereitet.
- None.
- FDA approval for AVERSA Fentanyl still pending
- Preferred share conversion contingent on uncertain FDA approval timeline
ORLANDO, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) (“Nutriband” or the “Company”) announced today that its Board of Directors has approved and declared a
Shareholders of record on July 25th 2025 will receive one preferred share for every four shares of common stock held. The pay date for shareholders to receive their new issuance will be August 5th.
Each preferred share will be convertible to one share of common stock following FDA approval of the Company’s AVERSA Fentanyl product.
If the preferred share remains unconverted it shall be entitled to a cash dividend paid from the profits of the company on an annual basis as decided by the board of Directors.
"Our core goal is to continue to create value for our shareholders particularly as we near closer to the commercialization of AVERSA fentanyl. We recently highlighted our Commercialization manufacturing process scale up with Kindeva and we are now laser focused on finalizing our development pathway to FDA approval," said Gareth Sheridan, CEO.
About AVERSA™ Abuse-Deterrent Transdermal Technology
Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Forms 10-K’s and Forms 10-Q’s, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
Contact Information:
Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com
SOURCE: Nutriband Inc.
FAQ
What is the preferred stock dividend ratio announced by Nutriband (NTRB)?
When will Nutriband (NTRB) shareholders receive their preferred stock dividend?
What are the conversion terms for Nutriband's (NTRB) new preferred shares?
What happens if Nutriband (NTRB) preferred shareholders don't convert their shares?
What is the status of Nutriband's (NTRB) AVERSA Fentanyl FDA approval process?
